Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies.

The MHC class I protein HLA-B27 is strongly associated with susceptibility to spondyloarthropathies and can cause arthritis when expressed in rats and mice, implying a direct role in disease pathogenesis. A prominent hypothesis to explain this role suggests that the unique peptide binding specificity of HLA-B27 confers an ability to present arthritogenic peptides. The B pocket, a region of the peptide binding groove that is an important determinant of allele-specific peptide binding, is thought to be critical for arthritogenicity. However, this hypothesis remains unproven. We show that in addition to its role in peptide selection, the B pocket causes a portion of the pool of assembling HLA-B27 heavy chains in the endoplasmic reticulum to misfold, resulting in their degradation in the cytosol. The misfolding phenotype is corrected by replacing the HLA-B27 B pocket with one from HLA-A2. Our results suggest an alternative to the arthritogenic peptide hypothesis. Misfolding and its consequences, rather than allele-specific peptide presentation, may underlie the strong link between the HLA-B27 B pocket and susceptibility to spondyloarthropathies.

[1]  H. Ploegh.  One‐Dimensional Isoelectric Focusing of Proteins in Slab Gels , 1995, Current protocols in protein science.

[2]  A. McMichael,et al.  Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. , 1999, Journal of immunology.

[3]  R. Kopito,et al.  Aggresomes: A Cellular Response to Misfolded Proteins , 1998, The Journal of cell biology.

[4]  S. Nigam,et al.  Folding of secretory and membrane proteins. , 1998, The New England journal of medicine.

[5]  A. Rickinson,et al.  HLA-B27 subtype polymorphism and CTL epitope choice: studies with EBV peptides link immunogenicity with stability of the B27:peptide complex. , 1998, Journal of immunology.

[6]  A. Goldberg,et al.  Proteasome inhibitors: valuable new tools for cell biologists. , 1998, Trends in cell biology.

[7]  R. Hammer,et al.  The Specificity of Peptides Bound to Human Histocompatibility Leukocyte Antigen (HLA)-B27 Influences the Prevalence of Arthritis in HLA-B27 Transgenic Rats , 1998, The Journal of experimental medicine.

[8]  J. Castro.  The pathogenetic role of HLA-B27 in chronic arthritis. , 1998 .

[9]  H. Luthra,et al.  Spontaneous inflammatory disease in HLA-B27 transgenic mice is independent of MHC class II molecules: a direct role for B27 heavy chains and not B27-derived peptides. , 1998, Journal of immunology.

[10]  P. Cresswell,et al.  Mechanisms of MHC class I--restricted antigen processing. , 1998, Annual review of immunology.

[11]  H. Rammensee,et al.  Naturally occurring A pocket polymorphism in HLA-B*2703 increases the dependence on an accessory anchor residue at P1 for optimal binding of nonamer peptides. , 1997, Journal of immunology.

[12]  E. Märker-Hermann,et al.  HLA-B27-derived peptides as autoantigens for T lymphocytes in ankylosing spondylitis. , 1997, Arthritis and rheumatism.

[13]  P. Cresswell,et al.  Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Singer,et al.  Incomplete endoplasmic reticulum (ER) retention in immature thymocytes as revealed by surface expression of "ER-resident" molecular chaperones. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Kopito.  ER Quality Control: The Cytoplasmic Connection , 1997, Cell.

[16]  Martin A. Nowak,et al.  Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS , 1997, Nature Medicine.

[17]  J. Shabanowitz,et al.  Susceptibility to ankylosing spondylitis correlates with the C‐terminal residue of peptides presented by various HLA‐B27 subtypes , 1997, European journal of immunology.

[18]  E. Coto,et al.  HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. , 1997, Tissue antigens.

[19]  H. Luthra,et al.  HLA-B27 heavy chains contribute to spontaneous inflammatory disease in B27/human beta2-microglobulin (beta2m) double transgenic mice with disrupted mouse beta2m. , 1996, The Journal of clinical investigation.

[20]  John E. Coligan,et al.  Current Protocols in Protein Science , 1996 .

[21]  P. Parham.  Presentation of HLA Class I‐Derived Peptides: Potential Involvement in Allorecognition and HLA‐B27‐Associated Arthritis , 1996, Immunological reviews.

[22]  P. Cresswell,et al.  The protease inhibitor, N-acetyl-L-leucyl-L-leucyl-leucyl-L- norleucinal, decreases the pool of major histocompatibility complex class I-binding peptides and inhibits peptide trimming in the endoplasmic reticulum , 1996, The Journal of experimental medicine.

[23]  M. Bogyo,et al.  The Human Cytomegalovirus US11 Gene Product Dislocates MHC Class I Heavy Chains from the Endoplasmic Reticulum to the Cytosol , 1996, Cell.

[24]  J. Dice,et al.  Roles of molecular chaperones in protein degradation , 1996, The Journal of cell biology.

[25]  R. Hammer,et al.  T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. , 1996, Journal of immunology.

[26]  H. Luthra,et al.  Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking beta 2-microglobulin: a model of human spondyloarthropathies , 1995, The Journal of experimental medicine.

[27]  R F Standaert,et al.  Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin , 1995, Science.

[28]  J. Heesemann,et al.  HLA-B27 as a relative risk factor in ankylosing enthesopathy in transgenic mice. , 1995, Human immunology.

[29]  P. Parham,et al.  Species-specific differences in chaperone interaction of human and mouse major histocompatibility complex class I molecules , 1995, The Journal of experimental medicine.

[30]  P. Cresswell,et al.  Assembly, peptide loading, and transport of MHC class I molecules in a calnexin-negative cell line. , 1995, Cold Spring Harbor symposia on quantitative biology.

[31]  D. Madden.  The three-dimensional structure of peptide-MHC complexes. , 1995, Annual review of immunology.

[32]  G. Burmester,et al.  Immunology of reactive arthritides. , 1995, Annual review of immunology.

[33]  K. Siminovitch,et al.  Investigating the genetic basis for ankylosing spondylitis. Linkage studies with the major histocompatibility complex region. , 1994, Arthritis and rheumatism.

[34]  M. Brenner,et al.  An unstable beta 2-microglobulin: major histocompatibility complex class I heavy chain intermediate dissociates from calnexin and then is stabilized by binding peptide , 1994, The Journal of experimental medicine.

[35]  V. Engelhard,et al.  Inhibition of T cell activation by a monoclonal antibody reactive against the alpha 3 domain of human MHC class I molecules. , 1994, Journal of immunology.

[36]  M. Brenner,et al.  Calnexin retains unassembled major histocompatibility complex class I free heavy chains in the endoplasmic reticulum , 1994, The Journal of experimental medicine.

[37]  S. Rowland-Jones,et al.  Differences in peptide presentation between B27 subtypes: the importance of the P1 side chain in maintaining high affinity peptide binding to B*2703. , 1994, Immunity.

[38]  B. Fleischer,et al.  HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis , 1993, The Lancet.

[39]  S. Rowland-Jones,et al.  Allele-specific B pocket transplant in class I major histocompatibility complex protein changes requirement for anchor residue at P2 of peptide. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Hammer,et al.  Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. , 1993, Journal of immunology.

[41]  H. Rammensee,et al.  Peptides naturally presented by MHC class I molecules. , 1993, Annual review of immunology.

[42]  H. Rammensee,et al.  Peptide motifs of closely related HLA class I molecules encompass substantial differences , 1992, European journal of immunology.

[43]  E. Degen,et al.  Efficient dissociation of the p88 chaperone from major histocompatibility complex class I molecules requires both beta 2- microglobulin and peptide , 1992, The Journal of experimental medicine.

[44]  P. Parham,et al.  The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. , 1992, Journal of immunology.

[45]  J. Sambrook,et al.  Protein folding in the cell , 1992, Nature.

[46]  D. R. Madden,et al.  Identification of self peptides bound to purified HLA-B27 , 1991, Nature.

[47]  R. Hammer,et al.  Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β 2m: An animal model of HLA-B27-associated human disorders , 1990, Cell.

[48]  P. Parham,et al.  Guilt by association: HLA-B27 and ankylosing spondylitis. , 1990, Immunology today.

[49]  H. Ploegh,et al.  Allele and locus‐specific differences in cell surface expression and the association of HLA class I heavy chain with β2‐microglobulin: differential effects of inhibition of glycosylation on class I subunit association , 1988, European journal of immunology.

[50]  A. McMichael,et al.  Recognition of HLA-B27 and related antigen by a monoclonal antibody. , 1982, Human immunology.

[51]  C. Barnstable,et al.  Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. , 1979, Journal of immunology.